Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00298064

Enrollment

Registered

2006-03-01

Start date

2005-12-31

Completion date

2005-12-31

Last updated

2023-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer, Cervix

Keywords

Cervical cancer, EGFR, cervical, genomic, DNA, markers, prognostic, gene, epidermal growth factor

Brief summary

The Tissue Repository will search for cases, pull slides, Paraffin-embedded tissue (PET) blocks.

Detailed description

This study is done to gather preliminary data for determining the best way to test EGFR expression in patients with cervical cancer who will receive treatment with EGFR inhibitors in the future. This study is designed to obtain preliminary data of genomic and phenotypic alterations of the EGFR pathway in high grade cervical intraepithelial lesions (HG-SIL) and invasive cervical cancers (CC) to be used later for therapeutic guidance and to evaluate genomic (over-expression, amplification, point mutations, etc.) and phenotypic alterations of other transduction pathways interacting with the EGFR pathway.

Interventions

GENETICTissue Repository

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

* Samples from patients diagnosed with HG-SIL (n=300) and CC (n=300) with a follow-up of at least 24 months, existing at the Department of Pathology will be retrieved by the Tissue Repository, de-identified them and provided with code numbers that will not be linked to patient's data.

Exclusion criteria

* None Specified.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026